MX2020006429A - Agente terapeutico para el glaucoma que comprende un agonista de fp y un bloqueador beta. - Google Patents

Agente terapeutico para el glaucoma que comprende un agonista de fp y un bloqueador beta.

Info

Publication number
MX2020006429A
MX2020006429A MX2020006429A MX2020006429A MX2020006429A MX 2020006429 A MX2020006429 A MX 2020006429A MX 2020006429 A MX2020006429 A MX 2020006429A MX 2020006429 A MX2020006429 A MX 2020006429A MX 2020006429 A MX2020006429 A MX 2020006429A
Authority
MX
Mexico
Prior art keywords
glaucoma
blocker
therapeutic agent
agonist
hydroxy
Prior art date
Application number
MX2020006429A
Other languages
English (en)
Inventor
Shinsaku Yamane
Satoshi Nakayama
Kazufumi Nagai
Kazumi Moriyuki
Tomohiro Karakawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2020006429A publication Critical patent/MX2020006429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se descubrió una terapia efectiva para el glaucoma, para ser provista como un medicamento. Una combinación de la presente invención, en particular una combinación de 4- 1(3S,SaR,6R,7R,SaS)-6-[(1E,3R)-4-(2,5-difluorofenoxi)-3- hidroxi-l-buten-l-il]-7-hidroxioctahidro-2H-ciclopenta[b]oxepin-3 -il}butanoato de 2-propanilo y un bloqueador p, es útil como un agente para tratar el glaucoma ya que la combinación mejora la acción reductora de la presión intraocular en comparación con una sola administración de cada fármaco y tiene un efecto de mantener la acción reductora de la presión intraocular.
MX2020006429A 2017-12-21 2018-12-20 Agente terapeutico para el glaucoma que comprende un agonista de fp y un bloqueador beta. MX2020006429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017244573 2017-12-21
PCT/JP2018/047102 WO2019124523A1 (ja) 2017-12-21 2018-12-20 ＦＰ作動薬とβ遮断薬を含有する緑内障治療剤

Publications (1)

Publication Number Publication Date
MX2020006429A true MX2020006429A (es) 2020-09-17

Family

ID=66993519

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006429A MX2020006429A (es) 2017-12-21 2018-12-20 Agente terapeutico para el glaucoma que comprende un agonista de fp y un bloqueador beta.

Country Status (14)

Country Link
US (1) US20210085636A1 (es)
EP (1) EP3730137B1 (es)
JP (1) JP7247894B2 (es)
KR (1) KR20200102435A (es)
CN (1) CN111479567B (es)
AU (1) AU2018390274C1 (es)
BR (1) BR112020012521A2 (es)
CA (1) CA3085747A1 (es)
EA (1) EA202091523A1 (es)
MX (1) MX2020006429A (es)
PH (1) PH12020550862A1 (es)
SG (1) SG11202005620QA (es)
TW (1) TWI809021B (es)
WO (1) WO2019124523A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404569A (zh) * 2022-04-22 2024-02-01 日商參天製藥股份有限公司 含有賽佩普斯特(Sepetaprost)之眼科用組合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2460801E (pt) * 2009-07-28 2014-08-29 Ono Pharmaceutical Co Composto bicíclico e a sua utilização para fins medicinais

Also Published As

Publication number Publication date
US20210085636A1 (en) 2021-03-25
PH12020550862A1 (en) 2021-05-17
WO2019124523A1 (ja) 2019-06-27
JP7247894B2 (ja) 2023-03-29
EP3730137B1 (en) 2024-03-20
AU2018390274A1 (en) 2020-07-02
JPWO2019124523A1 (ja) 2020-12-10
KR20200102435A (ko) 2020-08-31
CA3085747A1 (en) 2019-06-27
SG11202005620QA (en) 2020-07-29
CN111479567B (zh) 2023-05-23
TW201934542A (zh) 2019-09-01
TWI809021B (zh) 2023-07-21
AU2018390274C1 (en) 2024-02-29
BR112020012521A2 (pt) 2020-11-24
AU2018390274B2 (en) 2023-02-02
EP3730137A1 (en) 2020-10-28
EP3730137A4 (en) 2021-02-24
CN111479567A (zh) 2020-07-31
EA202091523A1 (ru) 2020-09-10

Similar Documents

Publication Publication Date Title
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
PH12017502092A1 (en) Topical pharmaceutical compositions
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
EP4324454A3 (en) Cross-linking agents and associated methods
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
CO2022007953A2 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
BR102015001449B8 (pt) composição de gel dental de papaína para tratamento não traumático de cáries e método para seu preparo
PH12020550862A1 (en) THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND á-BLOCKER
NZ751972A (en) Treatment of prurigo nodularis
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2022006523A (es) Composicion que comprende budesonida para uso oftalmico.
PH12020551620A1 (en) Compositions for preventing or treating dry eye
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
GEP20207144B (en) Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof
ZA202210027B (en) Compositions of vitamin a palmitate, processes for their preparation, uses and methods comprising them
MX2022011131A (es) Nuevo uso y metodo de tratamiento.
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин
EA201992816A1 (ru) Фармацевтическая композиция и лекарственная форма, которая включает (e)-4-(2-(аминометил)-3-фтораллилокси)-n-трет-бутилбензамид, способ их приготовления, способы лечения и их применения
EA201900418A1 (ru) Средство для терапии раневых или ожоговых поражений кожи
MX2022001200A (es) Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico.